Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Tablets: SOP for Microbial Limit Testing for Dispersible Tablets – V 2.0

Posted on By

Tablets: SOP for Microbial Limit Testing for Dispersible Tablets – V 2.0

Standard Operating Procedure for Microbial Limit Testing for Dispersible Tablets

Department Tablet
SOP No. SOP/TAB/082/2025
Supersedes SOP/TAB/082/2022
Page No. Page 1 of 6
Issue Date 01/03/2026
Effective Date 06/03/2026
Review Date 01/03/2027

1. Purpose

To establish a procedure for microbial limit testing of dispersible tablets, ensuring that the tablets meet the required microbiological standards for safe consumption.

2. Scope

This SOP applies to the microbial limit testing of dispersible tablets to ensure they comply with the specified limits for microbial contamination as per regulatory standards.

3. Responsibilities

  • Manufacturing Personnel: Responsible for providing representative samples of dispersible tablets for microbial testing and ensuring the tablets are free from visible defects.
  • Quality Control (QC): Responsible for conducting the microbial limit tests, recording the results, and ensuring compliance with microbiological standards.
  • Quality Assurance (QA): Ensures that the testing procedure is followed and reviews the results for batch approval and release.

4. Accountability

The QC Manager is accountable for ensuring that microbial limit testing is performed in compliance with this SOP and for reporting the results. The QA Manager is responsible for reviewing the results and approving the batch for release.

See also  Tablets: SOP for Preventive Action Reports (PAR) for Deviations - V 2.0

5. Procedure

5.1 Sample Collection

  1. Collect a representative sample of dispersible tablets from the batch, as specified in the batch record.
  2. The sample should consist of 6 tablets (or as specified in the batch record or pharmacopeial guidelines).
  3. Ensure that the tablets are free from defects such as cracks, chips, or contamination.
  4. Label the sample appropriately for identification during testing.

5.2 Preparation of Microbial Testing Apparatus

  1. Prepare the microbial testing apparatus, ensuring that it is clean and properly calibrated.
  2. Ensure that sterile equipment, including petri dishes, nutrient agar, and any necessary culture media, is available and prepared.
  3. Prepare an appropriate dilution of the sample tablets to obtain a suitable concentration for microbial testing.

5.3 Microbial Limit Test Procedure

  1. Prepare the tablet sample for testing by triturating or dissolving the required number of tablets in a suitable diluent, as per the pharmacopeial guidelines.
  2. Take an aliquot of the sample and inoculate it onto the prepared agar plates for microbial growth.
  3. Incubate the agar plates under suitable conditions for microbial growth (usually at 30°C–35°C for bacteria, and at 20°C–25°C for fungi, unless specified otherwise in the pharmacopeia).
  4. Allow the samples to incubate for the specified period (typically 48–72 hours), observing for any microbial growth.

5.4 Data Recording and Calculation

  1. After the incubation period, examine the plates for microbial growth, counting the number of colonies observed.
  2. Record the number of colony-forming units (CFUs) for each agar plate in the batch record (Annexure-1).
  3. Compare the results against the acceptance criteria specified in the batch record or pharmacopeial guidelines (e.g., total aerobic bacteria, yeast and molds, and specific pathogens).
See also  Tablets: SOP for Sampling Plan for In-Process Tablet Testing - V 2.0

5.5 Microbial Limit Test Acceptance Criteria

  1. Ensure that the tablet sample does not exceed the acceptable limit for microbial contamination, which is typically 1000 CFU/g for total aerobic bacteria and 100 CFU/g for yeast and molds, but may vary depending on the product specifications.
  2. If any sample exceeds the microbial limit, the batch should be investigated, and corrective actions should be documented in the deviation report (Annexure-2).

5.6 Documentation and Record-Keeping

  1. Document the microbial limit testing results, including the individual counts for each tablet sample, in the batch record (Annexure-1).
  2. Record any deviations from the microbial limit specifications in the deviation report (Annexure-2), along with the corrective actions taken.
  3. Ensure all records are signed, dated, and stored according to the company’s record retention policy for future audits and inspections.

5.7 Post-Test Cleanup

  1. Clean all equipment used in microbial testing, including petri dishes, dilution tubes, and culture media, according to the company’s cleaning SOP.
  2. Ensure that all testing equipment is properly stored and maintained in good working condition.

See also  Tablets: SOP for Automated In-Process Data Review Systems - V 2.0

6. Abbreviations

  • SOP: Standard Operating Procedure
  • GMP: Good Manufacturing Practice
  • QC: Quality Control
  • QA: Quality Assurance
  • CFU: Colony-Forming Unit

7. Documents

  1. Batch Record (Annexure-1)
  2. Deviation Report (Annexure-2)

8. References

  • USP <61> – Microbial Limits
  • 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals (US FDA)
  • European Pharmacopoeia (EP) – Microbial Limits for Tablets

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Batch Record

Batch Number Tablet Sample Microbial Count (CFU/g) Microbial Type Result
Batch 001 6 tablets 500 Total Aerobic Bacteria Pass

Annexure-2: Deviation Report

Deviation Date Batch Number Deviation Description Corrective Action Responsible Person
10/12/2025

You said:
Continue
ChatGPT said:
Here is the continuation of the SOP for “Microbial Limit Testing for Dispersible Tablets” in HTML format:

html
Copy

Batch 001 Microbial count exceeded specification Investigated raw material supplier and adjusted process controls John Doe

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial Version New SOP Creation QA Head
01/02/2025 2.0 Updated Microbial Testing Protocol Refined testing method and specifications QA Head
Tablet Manufacturing V2.0 Tags:GMP tablet manufacturing SOP, SOP for tablet production, SOP for tablet quality control, SOP tablet inspection process, SOP tablet packing and sealing, Tablet batch record review, Tablet blending SOP, Tablet cleaning and maintenance, Tablet coating procedure, Tablet compression SOP, Tablet disintegration test procedure, Tablet dissolution procedure, Tablet formulation SOP, Tablet friability testing SOP, Tablet labeling and packaging SOP, Tablet manufacturing equipment SOP, Tablet manufacturing SOP, Tablet manufacturing SOPs, Tablet packaging SOP, Tablet production procedure, Tablet quality assurance SOP, Tablet quality control SOP, Tablet sampling and in-process testing SOP, Tablet stability testing SOP, Tablet storage and handling procedure, Tablet uniformity testing procedure, Tablet weight variation SOP

Post navigation

Previous Post: Integrating JSAs with Standard Operating Procedures (SOPs) in Pharma Operations
Next Post: SOP for Inventory Control of Raw Materials in Quarantine – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version